On September 20, Yang Sheng, deputy director of the State Drug Administration, said at the press conference of the State Drug Administration that during the “15th Five-Year Plan” period, opinions will be issued to improve the drug safety responsibility system, promote the revision of laws and regulations such as the Medical Device Administration Law and the Regulations on the Protection of Chinese Medicines, comprehensively implement the Drug Administration Law implementation regulations, improve supporting systems, implement an action plan to raise standards for pharmaceuticals and medical devices, compile the 2030 edition of the Chinese Pharmacopoeia, prioritize the inclusion of essential drugs, medical insurance drugs and high-risk formulation varieties, and strengthen the research and formulation of standards in cutting-edge fields such as brain-computer interfaces to drive quality improvement through standard upgrades.

On September 20, Yang Sheng, deputy director of the State Drug Administration, said at the press conference of the State Drug Administration that during the “15th Five-Year Plan” period, opinions will be issued to improve the drug safety responsibility system, promote the revision of laws and regulations such as the Medical Device Administration Law and the Regulations on the Protection of Chinese Medicines, comprehensively implement the Drug Administration Law implementation regulations, improve supporting systems, implement an action plan to raise standards for pharmaceuticals and medical devices, compile the 2030 edition of the Chinese Pharmacopoeia, prioritize the inclusion of essential drugs, medical insurance drugs and high-risk formulation varieties, and strengthen the research and formulation of standards in cutting-edge fields such as brain-computer interfaces to drive quality improvement through standard upgrades.